LAB TEST

Claudin 18 (CLDN18) (43-14A) – Semi-Quantitative Immunohistochemistry

Semi-quantitative Claudin 18 IHC test to detect CLDN18.2 expression in gastric & GEJ cancers. Supports targeted therapy & precision oncology decisions.

Mayo Clinic Laboratories
TAT: 2 Weeks
Tissue
Dr. Dangs Lab Logo

Dr. Dangs Lab

Diagnostic Test

Claudin 18 (CLDN18) (43-14A) Test

Available through our international laboratory collaboration with Mayo Clinic Laboratories

Overview

The Claudin 18 (CLDN18) (43-14A) test is a semi-quantitative immunohistochemistry (IHC) assay, performed manually, to evaluate the presence and expression level of Claudin 18 protein in tissue specimens.

Claudin 18 is a tight junction protein expressed in the gastric mucosa and certain tumors, particularly:

  • Gastric adenocarcinomas
  • Gastroesophageal junction cancers

It has emerging significance as a predictive biomarker for targeted therapy selection — notably for anti-CLDN18.2 monoclonal antibody treatments (e.g., zolbetuximab).

Clinical Utility

This test aids in:

  • Identifying CLDN18.2 expression in gastric and gastroesophageal junction adenocarcinomas.
  • Stratifying patients for potential eligibility for targeted therapy.
  • Providing semi-quantitative scoring of protein expression to guide clinical decision-making.

Specimen Requirements

  • Specimen Type: Formalin-fixed, paraffin-embedded (FFPE) tissue block or unstained slides from tumor tissue.
  • Preferred Source: Primary tumor or metastatic site.
  • Number of Slides: As per testing protocol (typically 1–2 unstained slides at 4–5 μm thickness).

Clinical Background

CLDN18.2 is a promising therapeutic target in gastric and gastroesophageal cancers.

  • Overexpression has been linked to tumor progression.
  • May predict response to specific monoclonal antibody treatments.
  • The semi-quantitative IHC method provides precise, reproducible results, helping oncologists identify candidates for precision oncology approaches.

Turnaround Time

  • Estimated: Typically within 2–4 business days from receipt at the reference laboratory.

Advantages of the Claudin 18 (CLDN18) (43-14A) Test

  • Enables personalized cancer treatment planning
  • Performed by a world-class reference pathology team
  • High specificity for CLDN18.2 detection
  • Supports clinical trial and targeted therapy eligibility assessment

These advantages align with functional medicine tests, integrated medicine testing, and preventive longevity tests offered at top functional health centres and longevity labs in Delhi / India.

Found this helpful?

Share this test information with others who might need it!